Drug Trial Radar · NCT01393912
PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma
Last checked: Nov 19, 2026Latest source record: Apr 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Jul 2011
Primary completion
Sep 2014
Study completion Oct 2016
Sponsor
- Lead sponsor
- St. Jude Children's Research HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Arog Pharmaceuticals, Inc.; The V Foundation for Cancer Research
- First posted
- Jul 13, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 months, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I clinical trial evaluating crenolanib (CP-868,596), an inhibitor of Platelet Derived Growth Factor Receptor (PDGFR)-kinase in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum A) or in recurrent, progressive or refractory High Grade Glioma (HGG) including DIPG (Stratum B). This study drug targets the most commonly amplified region of genome found in DIPG and pediatric high grade glioma (HGG) which encodes for the PDGF receptor kinase. An oral investigational agent crenolanib will be administered daily during and after local radiation therapy (RT) in Diffuse Intrinsic Pontine Glioma DIPG (Stratum A), or daily for children with recurrent/refractory HGG (Stratum B).
Conditions
- Diffuse Intrinsic Pontine Glioma
- Progressive or Refractory High-Grade Glioma
Interventions
CrenolanibDrug
Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimate the maximum tolerated dose (MTD) of crenolanib in pediatric research participants with newly diagnosed DIPGTime frame: 2.5 years
- Estimate the MTD of crenolanib in children and young adults with recurrent/refractory HGG including DIPGTime frame: 2.5years
- Characterize the pharmacokinetics of crenolanib in pediatric patients and relate drug disposition to toxicityTime frame: 2.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Jude Children's Research Hospital
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.